219 related articles for article (PubMed ID: 22450781)
1. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer.
Carvalho J; van Grieken NC; Pereira PM; Sousa S; Tijssen M; Buffart TE; Diosdado B; Grabsch H; Santos MA; Meijer G; Seruca R; Carvalho B; Oliveira C
J Pathol; 2012 Sep; 228(1):31-44. PubMed ID: 22450781
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer.
Rossi T; Tedaldi G; Petracci E; Abou Khouzam R; Ranzani GN; Morgagni P; Saragoni L; Monti M; Calistri D; Ulivi P; Molinari C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509966
[No Abstract] [Full Text] [Related]
4. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Mediates the Regulation of S100A4 on E-cadherin Expression and the Proliferation, Migration of Gastric Cancer Cells.
Liu S; Chen D; Shen W; Chen L; Yu A; Fu H; Sun K; Sun X
Hepatogastroenterology; 2015 May; 62(139):737-41. PubMed ID: 26897964
[TBL] [Abstract][Full Text] [Related]
6. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.
Kurashige J; Kamohara H; Watanabe M; Hiyoshi Y; Iwatsuki M; Tanaka Y; Kinoshita K; Saito S; Baba Y; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S656-64. PubMed ID: 22311119
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Ibarrola-Villava M; Llorca-Cardeñosa MJ; Tarazona N; Mongort C; Fleitas T; Perez-Fidalgo JA; Roselló S; Navarro S; Ribas G; Cervantes A
Oncotarget; 2015 Sep; 6(29):26935-45. PubMed ID: 26334097
[TBL] [Abstract][Full Text] [Related]
10. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.
Rosivatz E; Becker I; Specht K; Fricke E; Luber B; Busch R; Höfler H; Becker KF
Am J Pathol; 2002 Nov; 161(5):1881-91. PubMed ID: 12414534
[TBL] [Abstract][Full Text] [Related]
12. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.
Cong N; Du P; Zhang A; Shen F; Su J; Pu P; Wang T; Zjang J; Kang C; Zhang Q
Oncol Rep; 2013 Apr; 29(4):1579-87. PubMed ID: 23381389
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of microRNA-200 in EBV-associated gastric carcinoma.
Shinozaki A; Sakatani T; Ushiku T; Hino R; Isogai M; Ishikawa S; Uozaki H; Takada K; Fukayama M
Cancer Res; 2010 Jun; 70(11):4719-27. PubMed ID: 20484038
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Tryndyak VP; Beland FA; Pogribny IP
Int J Cancer; 2010 Jun; 126(11):2575-83. PubMed ID: 19839049
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c.
Nakada C; Matsuura K; Tsukamoto Y; Tanigawa M; Yoshimoto T; Narimatsu T; Nguyen LT; Hijiya N; Uchida T; Sato F; Mimata H; Seto M; Moriyama M
J Pathol; 2008 Dec; 216(4):418-27. PubMed ID: 18925646
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
19. miR-137 Modulates Human Gastric Cancer Cell Proliferation, Apoptosis, and Migration by Targeting EZH2.
Weng XQ; Wang W
Crit Rev Eukaryot Gene Expr; 2022; 32(4):31-40. PubMed ID: 35695663
[TBL] [Abstract][Full Text] [Related]
20. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]